SCHEMBL16508299

SCHEMBL16508299

CCc1cc(-c2ccc[nH]c2=O)c2nnc(-c3ccc(NS(C)(=O)=O)cc3)cc2c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.49
PIP4K2A P48426 2/20 0.37
PIP4K2B P78356 2/20 0.37
PIP4K2C Q8TBX8 1/20 0.37
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703309 0.87 CYP3A4 (0.57) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL16508264 0.86 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL16508295 0.86 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL15188916 0.84 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL625962 0.73 CYP3A4 (0.57) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL1703305 0.73 CYP3A4 (0.57) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL1702764 0.73 CYP3A4 (0.57) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL16508271 0.73 CYP3A4 (0.46) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL16508262 0.72 DYRK1B (0.41) IKBKBCHUKPIK3CA
SCHEMBL16508267 0.71 NPC1 (0.41) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, ZC3HAV1, IRF3 CYP3A4 55/4885PIP4K2A 2698/4885PIP4K2B 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.